These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 14738304)
1. Basiliximab monotherapy following B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy. Venzke A; Ganschow R; Grabhorn E; Rogiers X; Burdelski M Pediatr Transplant; 2003 Oct; 7(5):404-7. PubMed ID: 14738304 [TBL] [Abstract][Full Text] [Related]
2. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045 [TBL] [Abstract][Full Text] [Related]
3. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588 [TBL] [Abstract][Full Text] [Related]
4. Use of basiliximab in pediatric liver transplantation for Langerhans cell histiocytosis. Rajwal SR; Stringer MD; Davison SM; Gerrard M; Glaser A; Tanner MS; McClean P Pediatr Transplant; 2003 Jun; 7(3):247-51. PubMed ID: 12756053 [TBL] [Abstract][Full Text] [Related]
5. First experience with basiliximab in pediatric liver graft recipients. Ganschow R; Broering DC; Stuerenburg I; Rogiers X; Hellwege HH; Burdelski M Pediatr Transplant; 2001 Oct; 5(5):353-8. PubMed ID: 11560755 [TBL] [Abstract][Full Text] [Related]
6. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation. Arora N; McKiernan PJ; Beath SV; deVille de Goyet J; Kelly DA Pediatr Transplant; 2002 Jun; 6(3):214-8. PubMed ID: 12100505 [TBL] [Abstract][Full Text] [Related]
7. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Gruttadauria S; Vasta F; Mandalà L; Cintorino D; Piazza T; Spada M; Verzaro R; Gridelli B Transplant Proc; 2005; 37(6):2611-3. PubMed ID: 16182762 [TBL] [Abstract][Full Text] [Related]
8. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. Aw MM; Taylor RM; Verma A; Parke A; Baker AJ; Hadzic D; Muiesan P; Rela M; Heaton ND; Mieli-Vergani G; Dhawan A Transplantation; 2003 Mar; 75(6):796-9. PubMed ID: 12660504 [TBL] [Abstract][Full Text] [Related]
9. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Clark G; Walsh G; Deshpande P; Koffman G Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256 [TBL] [Abstract][Full Text] [Related]
11. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Lupo L; Panzera P; Tandoi F; Carbotta G; Giannelli G; Santantonio T; Rendina M; Gentile A; Memeo V Transplantation; 2008 Oct; 86(7):925-31. PubMed ID: 18852657 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466 [TBL] [Abstract][Full Text] [Related]
13. Basiliximab in the therapy of acute rejection after organ transplantation. Chariat MN; Erren M; Chariat M; Deng M; Wolters HH; Dietl KH Transplant Proc; 2001 May; 33(3):2380. PubMed ID: 11377567 [No Abstract] [Full Text] [Related]
14. Initial immunosuppression with or without basiliximab: a comparative study. Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457 [TBL] [Abstract][Full Text] [Related]
15. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. Gruttadauria S; Cintorino D; Piazza T; Mandala L; Doffria E; Musumeci A; Di Trapani G; Arcadipane A; Scianna G; Spada M; Verzaro R; Volpes R; Vizzini G; Palazzo U; Minervini M; Marsh JW; Marcos A; Gridelli B Transplant Proc; 2006 May; 38(4):1106-8. PubMed ID: 16757278 [TBL] [Abstract][Full Text] [Related]
16. Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure. Shigeta T; Sakamoto S; Uchida H; Sasaki K; Hamano I; Kanazawa H; Fukuda A; Kawai T; Onodera M; Nakazawa A; Kasahara M Pediatr Transplant; 2014 Dec; 18(8):860-7. PubMed ID: 25311536 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Vester U; Kranz B; Testa G; Malagò M; Beelen D; Broelsch CE; Hoyer PF Pediatr Transplant; 2001 Aug; 5(4):297-301. PubMed ID: 11472610 [TBL] [Abstract][Full Text] [Related]
18. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Filipponi F; Callea F; Salizzoni M; Grazi GL; Fassati LR; Rossi M; Risaliti A; Burra P; Agnes S; De Carlis L; Valente U; Ferrara R; Pisati R Transplantation; 2004 Nov; 78(10):1488-95. PubMed ID: 15599313 [TBL] [Abstract][Full Text] [Related]